Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris

NCT00797953 is registered in ClinicalTrials.gov with Tasly Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00797953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00797953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris
Lead sponsor
Tasly Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
January 31, 2010
Enrollment
124 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris